Aclarion, Inc. (NASDAQ:ACON – Get Free Report) Director Amanda Williams purchased 5,857 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was acquired at an average price of $2.73 per share, for a total transaction of $15,989.61. Following the completion of the purchase, the director directly owned 25,857 shares of the company’s stock, valued at $70,589.61. This represents a 29.28% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Aclarion Trading Down 6.1%
ACON opened at $2.60 on Wednesday. The company has a market cap of $7.49 million, a P/E ratio of -0.35 and a beta of 1.22. Aclarion, Inc. has a 1-year low of $1.95 and a 1-year high of $12.03. The company’s 50 day moving average is $2.68 and its 200-day moving average is $2.98.
Aclarion (NASDAQ:ACON – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. On average, equities analysts forecast that Aclarion, Inc. will post -4.51 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on ACON shares. Wall Street Zen raised Aclarion from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings raised Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Finally, Ascendiant Capital Markets upped their price objective on Aclarion from $7.00 to $7.50 and gave the company a “buy” rating in a research note on Friday, May 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.50.
Read Our Latest Stock Analysis on Aclarion
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.
Featured Articles
- Five stocks we like better than Aclarion
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
